A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

Ryo Watanabe, Jun Ichi Suzuki, Kouji Wakayama, Yasuhiro Maejima, Munehisa Shimamura, Hiroshi Koriyama, Hironori Nakagami, Hidetoshi Kumagai, Yuichi Ikeda, Hiroshi Akazawa, Ryuichi Morishita, Issei Komuro, Mitsuaki Isobe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction in association with an elevation in the serum anti-Ang II antibody titer. Furthermore, any detrimental effects of the Ang II vaccine were not observed in the rats that underwent sham operations. Treatment with immunized serum from Ang II vaccine-injected rats significantly suppressed post-MI cardiac dysfunction in MI rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. Thus, our present study demonstrates that the Ang II vaccine may provide a promising novel therapeutic strategy for preventing heart failure.

Original languageEnglish (US)
Article number43920
JournalScientific Reports
Volume7
DOIs
StatePublished - Mar 7 2017

Fingerprint

Subunit Vaccines
Angiotensin II
Myocardial Infarction
Vaccines
Heart Failure
Serum
Therapeutics
Fibroblasts
Hypertension
Drug Therapy
Injections
Antibodies

ASJC Scopus subject areas

  • General

Cite this

Watanabe, R., Suzuki, J. I., Wakayama, K., Maejima, Y., Shimamura, M., Koriyama, H., ... Isobe, M. (2017). A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific Reports, 7, [43920]. https://doi.org/10.1038/srep43920

A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. / Watanabe, Ryo; Suzuki, Jun Ichi; Wakayama, Kouji; Maejima, Yasuhiro; Shimamura, Munehisa; Koriyama, Hiroshi; Nakagami, Hironori; Kumagai, Hidetoshi; Ikeda, Yuichi; Akazawa, Hiroshi; Morishita, Ryuichi; Komuro, Issei; Isobe, Mitsuaki.

In: Scientific Reports, Vol. 7, 43920, 07.03.2017.

Research output: Contribution to journalArticle

Watanabe, R, Suzuki, JI, Wakayama, K, Maejima, Y, Shimamura, M, Koriyama, H, Nakagami, H, Kumagai, H, Ikeda, Y, Akazawa, H, Morishita, R, Komuro, I & Isobe, M 2017, 'A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction', Scientific Reports, vol. 7, 43920. https://doi.org/10.1038/srep43920
Watanabe, Ryo ; Suzuki, Jun Ichi ; Wakayama, Kouji ; Maejima, Yasuhiro ; Shimamura, Munehisa ; Koriyama, Hiroshi ; Nakagami, Hironori ; Kumagai, Hidetoshi ; Ikeda, Yuichi ; Akazawa, Hiroshi ; Morishita, Ryuichi ; Komuro, Issei ; Isobe, Mitsuaki. / A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. In: Scientific Reports. 2017 ; Vol. 7.
@article{1698ac87806e4a85904cb8c9ee99399e,
title = "A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction",
abstract = "A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction in association with an elevation in the serum anti-Ang II antibody titer. Furthermore, any detrimental effects of the Ang II vaccine were not observed in the rats that underwent sham operations. Treatment with immunized serum from Ang II vaccine-injected rats significantly suppressed post-MI cardiac dysfunction in MI rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. Thus, our present study demonstrates that the Ang II vaccine may provide a promising novel therapeutic strategy for preventing heart failure.",
author = "Ryo Watanabe and Suzuki, {Jun Ichi} and Kouji Wakayama and Yasuhiro Maejima and Munehisa Shimamura and Hiroshi Koriyama and Hironori Nakagami and Hidetoshi Kumagai and Yuichi Ikeda and Hiroshi Akazawa and Ryuichi Morishita and Issei Komuro and Mitsuaki Isobe",
year = "2017",
month = "3",
day = "7",
doi = "10.1038/srep43920",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

AU - Watanabe, Ryo

AU - Suzuki, Jun Ichi

AU - Wakayama, Kouji

AU - Maejima, Yasuhiro

AU - Shimamura, Munehisa

AU - Koriyama, Hiroshi

AU - Nakagami, Hironori

AU - Kumagai, Hidetoshi

AU - Ikeda, Yuichi

AU - Akazawa, Hiroshi

AU - Morishita, Ryuichi

AU - Komuro, Issei

AU - Isobe, Mitsuaki

PY - 2017/3/7

Y1 - 2017/3/7

N2 - A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction in association with an elevation in the serum anti-Ang II antibody titer. Furthermore, any detrimental effects of the Ang II vaccine were not observed in the rats that underwent sham operations. Treatment with immunized serum from Ang II vaccine-injected rats significantly suppressed post-MI cardiac dysfunction in MI rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. Thus, our present study demonstrates that the Ang II vaccine may provide a promising novel therapeutic strategy for preventing heart failure.

AB - A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction in association with an elevation in the serum anti-Ang II antibody titer. Furthermore, any detrimental effects of the Ang II vaccine were not observed in the rats that underwent sham operations. Treatment with immunized serum from Ang II vaccine-injected rats significantly suppressed post-MI cardiac dysfunction in MI rats and Ang II-induced remodeling-associated signaling in cardiac fibroblasts. Thus, our present study demonstrates that the Ang II vaccine may provide a promising novel therapeutic strategy for preventing heart failure.

UR - http://www.scopus.com/inward/record.url?scp=85014965910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014965910&partnerID=8YFLogxK

U2 - 10.1038/srep43920

DO - 10.1038/srep43920

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 43920

ER -